Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Trade Show

Aura Biosciences Announces Participation at Upcoming Investor Conferences


Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that members of Aura's executive team will participate in the following upcoming investor conferences:

About Aura Biosciences

Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 for the treatment of primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit www.aurabiosciences.com.


These press releases may also interest you

at 23:33
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 - Exclusive Report by 360iResearch
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

at 23:13
DHGATE Group wins "Best B2B Cross-Border e-commerce Marketplace Company China 2024" at the Global Business & Finance Magazine
DHGATE Group has won the "Best B2B Cross-Border E-Commerce Marketplace Company China 2024" award at the Global Business & Finance Magazine Awards. The award recognizes leading enterprises with innovation and leadership from various industries, and...

at 23:13
Fluency Tops G2 Rankings for the Fourth Consecutive Quarter
For the fourth straight quarter, Fluency has been named #1 by G2 in several key customer-centric...

at 23:06
Vipshop Filed 2023 Annual Report on Form 20-F
Vipshop Holdings Limited , a leading online discount retailer for brands in China ("Vipshop" or the "Company"), today announced that the Company has filed its annual report on Form 20-F that includes its audited financial statements for three years...

at 22:54
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

at 22:18
SKT collaborates with Aptos Labs, Brevan Howard and Microsoft to bring global institutional finance on-chain with Aptos Ascend
SK Telecom today announced a collaboration with Aptos Labs, Brevan Howard, and Microsoft to deliver to the global financial market Aptos Ascend, a suite of end-to-end institutional solutions including a permissioned network and Digital Asset...

More news about Science and technology...


News published on and distributed by: